SAB-142 targets beta-cell preservation in newly diagnosed T1D; the SAFEGUARD Phase 2b readout will determine whether Phase 1 C-peptide signals translate to registrational efficacy

Bull

A positive readout would show statistically significant preservation of stimulated C-peptide AUC at 12 months versus placebo, consistent with or exceeding the super responder rate seen in Phase 1, alongside a clean safety profile with no lymphodepletion or immunogenicity on repeat dosing. This would validate the hyperimmunized polyclonal antibody platform, support BLA submission, and position SAB-142 as a potential best-in-class beta-cell preservation therapy in newly diagnosed T1D.

Bear

The most likely failure mode is dilution of the Phase 1 signal in a larger, heterogeneous population — the Phase 1 cohort was only four treated patients, and the super responder phenomenon may not replicate at scale or across a broader range of disease duration and baseline C-peptide levels. Secondary failure modes include insufficient durability of C-peptide preservation beyond the primary endpoint window, or unexpected immunogenicity signals that complicate the repeat-dosing narrative.